Latest Ratios: P/E Ratio 9.1x · EV/EBITDA 11.2x · ROE 621.9%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1B | $1.7B | $899M | $509M | $145M | $1.4B | — | — | — |
| Enterprise Value | $3.2B | $2.9B | $2.3B | $2.0B | $1.5B | $2.6B | — | — | — |
| P/E Ratio → | 9.14 | 7.70 | — | — | — | — | — | — | — |
| P/S Ratio | 0.86 | 0.71 | 0.44 | 0.27 | 0.08 | 0.81 | — | — | — |
| P/B Ratio | 10.61 | 8.93 | — | — | — | 2.14 | — | — | — |
| P/FCF | 18.21 | 15.13 | 34.15 | 30.75 | — | — | — | — | — |
| P/OCF | 17.10 | 14.21 | 27.54 | 22.45 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.19 | 1.14 | 1.04 | 0.83 | 1.57 | — | — | — |
| EV / EBITDA | 11.21 | 9.98 | 13.55 | 51.46 | — | — | — | — | — |
| EV / EBIT | 12.21 | 11.51 | 14.83 | 216.55 | — | — | — | — | — |
| EV / FCF | — | 25.15 | 88.02 | 118.65 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.1% | 33.1% | 31.4% | 31.4% | 30.9% | 32.3% | 30.4% | 30.3% | 31.5% |
| Operating Margin | 10.9% | 10.9% | 6.9% | 0.4% | -35.9% | -2.2% | -0.2% | 2.8% | 3.1% |
| Net Profit Margin | 9.2% | 9.2% | -0.5% | -7.1% | -37.0% | -7.0% | -3.8% | -5.5% | -3.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 621.9% | 621.9% | — | — | -208.9% | -25.9% | -21.2% | -24.8% | -13.7% |
| ROA | 12.2% | 12.2% | -0.7% | -8.1% | -32.7% | -5.6% | -3.3% | -4.9% | -3.0% |
| ROIC | 15.1% | 15.1% | 8.0% | 0.5% | -29.8% | -1.7% | -0.2% | 2.2% | 2.3% |
| ROCE | 18.5% | 18.5% | 11.1% | 0.6% | -38.1% | -2.0% | -0.2% | 2.8% | 2.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 6.91 | 6.91 | — | — | — | 2.04 | 4.60 | 3.98 | 2.76 |
| Debt / EBITDA | 4.65 | 4.65 | 8.79 | 39.28 | — | — | 45.94 | 16.37 | 18.69 |
| Net Debt / Equity | — | 5.91 | — | — | — | 1.99 | 4.08 | 3.97 | 2.74 |
| Net Debt / EBITDA | 3.98 | 3.98 | 8.29 | 38.13 | — | — | 40.81 | 16.32 | 18.53 |
| Debt / FCF | — | 10.02 | 53.87 | 87.90 | — | — | 10.76 | — | 468.24 |
| Interest Coverage | 1.79 | 1.79 | 1.00 | 0.06 | -5.23 | -0.77 | 0.38 | 0.19 | 0.34 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.32 | 1.32 | 0.98 | 0.89 | 0.83 | 0.81 | 1.31 | 1.11 | 1.08 |
| Quick Ratio | 1.32 | 1.32 | 0.98 | 0.89 | 0.83 | 0.81 | 1.31 | 1.11 | 1.08 |
| Cash Ratio | 0.46 | 0.46 | 0.21 | 0.12 | 0.06 | 0.09 | 0.53 | 0.02 | 0.04 |
| Asset Turnover | — | 1.20 | 1.22 | 1.17 | 1.04 | 0.72 | 0.81 | 0.88 | 0.81 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 47.01 | 50.06 | 47.34 | 46.07 | 48.99 | 44.16 | 43.33 | 53.12 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 10.9% | 13.0% | — | — | — | — | — | — | — |
| FCF Yield | 5.5% | 6.6% | 2.9% | 3.3% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $215M | $193M | $190M | $186M | $185M | $186M | $186M | $180M |
High debt service burden
Based on current market data, AVAH trades at a TTM P/E of 8.25, which appears to reflect a significant complexity discount compared to peers like Addus HomeCare, potentially underestimating the long-term stability of the company's specialized pediatric private duty nursing revenue streams in the current market environment.
The forward P/E of 14.92 suggests that investors are pricing in a recovery in earnings, yet the valuation remains compressed relative to the broader healthcare services sector. This discrepancy may stem from the market's skepticism regarding the company's ability to manage its high leverage while simultaneously scaling its diverse service segments.
As reported in recent financial statements, AVAH's ROIC has struggled to exceed 5% over the last ten quarters, a trend that suggests the company's aggressive acquisition strategy has yet to generate returns that meaningfully exceed the cost of capital required to maintain its complex debt structure.
The persistent reliance on goodwill, which constitutes over half of total assets, indicates that the company's return profile is heavily skewed by historical M&A activity. Investors should monitor whether management can shift toward organic growth, as the current ROIC levels suggest that the existing asset base is not yet compounding value effectively.
According to quarterly filings, the company's DSO has remained relatively stable near 47 days, yet the significant fluctuations in working capital observed in recent periods suggest that revenue cycle management remains a primary operational challenge that directly impacts the company's ability to maintain consistent cash flow.
The lack of inventory data is expected given the service-oriented business model, but the reliance on government payers makes the company vulnerable to payment delays. The current CCC trend warrants further investigation to determine if administrative bottlenecks are hindering the conversion of billed services into actual cash receipts.
Based on reported figures, AVAH's debt-to-equity ratio of 6.26 in 2026Q1 highlights a highly leveraged capital structure that leaves the company with limited flexibility, particularly when compared to the more conservative balance sheets of peers like Healthcare Services Group, which maintain significantly lower debt profiles.
The interest coverage ratio, which has fluctuated between 0.17 and 2.60 over the last ten quarters, indicates that the company's ability to service its debt is highly sensitive to quarterly earnings volatility. This leverage profile remains a critical risk factor that could limit the company's ability to invest in future growth initiatives.
The P/E ratio is frequently misapplied to AVAH, as it obscures the significant impact of non-operating accounting adjustments and high interest expenses that distort net income, making it a poor proxy for the company's underlying cash-generating capability in the high-acuity home care industry.
Analysts should instead prioritize EV/EBITDA or P/FCF to better assess the company's operational performance, as these metrics are less susceptible to the volatility of non-recurring items and the company's specific capital structure. Relying solely on P/E may lead to an inaccurate assessment of the firm's true earning power.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AVAH stock.
Aveanna Healthcare Holdings Inc.'s current P/E ratio is 9.1x. The historical average is 7.7x. This places it at the 100th percentile of its historical range.
Aveanna Healthcare Holdings Inc.'s current EV/EBITDA is 11.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.0x.
Aveanna Healthcare Holdings Inc.'s return on equity (ROE) is 621.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -58.9%.
Based on historical data, Aveanna Healthcare Holdings Inc. is trading at a P/E of 9.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Aveanna Healthcare Holdings Inc. has 33.1% gross margin and 10.9% operating margin. Operating margin between 10-20% is typical for established companies.
Aveanna Healthcare Holdings Inc.'s Debt/EBITDA ratio is 4.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.